CGEM Earnings Date: Nov 5, 2026 (Estimated) — Cullinan Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is CGEM's next earnings date?
Cullinan Therapeutics, Inc. (CGEM) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.84 on revenue of $2.0M.
How did CGEM do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Cullinan Therapeutics, Inc. posted EPS of -$0.81 versus the -$0.80 estimate, a miss of 1.2%. Revenue was $0 against a $3.7M estimate. The stock's 1-day post-earnings move was +1.9%.
How much does CGEM stock move after earnings?
CGEM beat EPS estimates in 7 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 3.6% (up or down) in the day after earnings.
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.80 | -0.81 | +1.22% | $0 | ❌ Miss | +1.93% | +11.30% | +25.84% |
| 2026-05-07 | Q1 2026 | -0.84 | -0.75 | +10.71% | $0 | ✅ Beat | -1.80% | +8.94% | -9.87% |
| 2026-03-10 | Q4 2025 | -0.82 | -0.77 | +6.10% | $0 | ✅ Beat | -2.61% | -8.36% | -2.29% |
| 2025-02-27 | Q4 2024 | -0.80 | -0.73 | +8.75% | $0 | ✅ Beat | +1.89% | -0.24% | -1.89% |
| 2024-11-07 | Q3 2024 | -0.81 | -0.69 | +14.81% | $0 | ✅ Beat | -5.46% | -4.19% | -20.75% |
| 2024-05-15 | Q1 2024 | -0.95 | -0.86 | +9.47% | $0 | ✅ Beat | -10.89% | -13.40% | -29.34% |
| 2024-03-14 | Q4 2023 | -0.96 | -0.54 | +43.75% | $0 | ✅ Beat | -0.41% | -8.54% | -1.83% |
| 2023-11-08 | Q3 2023 | -0.92 | -0.91 | +1.09% | $0 | ✅ Beat | — | — | — |
Showing last 8 quarters.